Prosecution Insights
Last updated: April 19, 2026
Application No. 17/759,806

COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE, MYODEGENERATIVE, AND LYSOSOMAL STORAGE DISORDERS

Final Rejection §102
Filed
Jul 29, 2022
Examiner
ROZOF, TIMOTHY R
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Georgetown University
OA Round
2 (Final)
73%
Grant Probability
Favorable
3-4
OA Rounds
2y 2m
To Grant
97%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allow Rate
690 granted / 951 resolved
+12.6% vs TC avg
Strong +24% interview lift
Without
With
+24.0%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 2m
Avg Prosecution
32 currently pending
Career history
983
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
20.1%
-19.9% vs TC avg
§102
34.4%
-5.6% vs TC avg
§112
23.5%
-16.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 951 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This is a response to Applicant’s communication filed on January 13, 2026. Application No. 17/759,806, is a 371 of PCT/US2021/015772, filed January 29, 2021, which claims the benefit of U.S. Provisional application No. 62/967,345, filed January 29, 2020. In a preliminary amendment filed January 23, 2023, Applicant cancelled claims 15, 18, 20, and 25-50. Claims 8-14, 16, 17, 19, and 21-24 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention. Claims 2 and 4-7 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species. The elections were made without traverse in the reply filed on September 3, 2025. Claims 1 and 3 are examined below. Rejections Withdrawn The rejection of claim 1 under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention, because of the phrase “e.g.” as well as “R10 (as not defined), is/are withdrawn in view of Applicant’s January 13, 2026, Amendment & Remarks. The rejection of claims 1 and 3 under 35 U.S.C. 102(a)(1) as being anticipated by Otevrel et al., 18(9) Molecules 10648-10670 (2013), is withdrawn in view of Applicant’s January 13, 2026, Amendment & Remarks. The rejection of claims 1 is under 35 U.S.C. 102(a)(1) as being anticipated by Niementowski, St. V., 40 Berichte der Deutschen Chemischen Gesellschaft 4285-94 (1908), is withdrawn in view of Applicant’s January 13, 2026, Amendment & Remarks. New Rejection Necessitated by Applicant’s January 13, 2026, Amendment Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim 1 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Hamara, JP43020294 (citing the CAS Abstract). The CAS Abstract for Hamara discloses the following compounds: PNG media_image1.png 214 291 media_image1.png Greyscale PNG media_image2.png 180 329 media_image2.png Greyscale (Hamara, citing the CAS Abstract for the compounds depicted above.) This compound reads on a compound of Formula I, wherein Formula I, R1, 2, 4,-7 are H (hydrogen); and R3 is an NH-methyl-substituted aryl (phenyl). Conclusion Claims 1 is not allowed. Claim 3 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIMOTHY R ROZOF whose telephone number is (571)270-5992. The examiner can normally be reached on Monday - Friday, 9:00 a.m. -5:00 p.m.. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached on (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TIMOTHY R ROZOF/ Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Jul 29, 2022
Application Filed
Oct 18, 2025
Non-Final Rejection — §102
Jan 13, 2026
Response Filed
Feb 20, 2026
Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594259
TREATMENT REGIMEN FOR THE TREATMENT OF NEUROLOGICAL DISEASES OR CONDITIONS
2y 5m to grant Granted Apr 07, 2026
Patent 12595264
HETEROCYCLIC GLP-1 AGONISTS
2y 5m to grant Granted Apr 07, 2026
Patent 12595255
HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES
2y 5m to grant Granted Apr 07, 2026
Patent 12577204
A SOLUTION OF TEMPO-DERIVATIVES FOR USE AS ELECTROLYTE IN REDOX-FLOW CELLS
2y 5m to grant Granted Mar 17, 2026
Patent 12577205
HYDROGENATION OF IMINES BY PALLADIUM BASED CATALYST
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
73%
Grant Probability
97%
With Interview (+24.0%)
2y 2m
Median Time to Grant
Moderate
PTA Risk
Based on 951 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month